CYH:NYE-Community Health Systems, Inc

COMMON STOCK | Medical Care | NYE

Last Closing Price

USD 4.46

Change

+0.18 (+4.21)%

Market Cap

USD 0.49B

Volume

1.81M

Average Target Price

USD 5.00 (+12.11%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Community Health Systems, Inc., together with its subsidiaries, owns, leases, and operates general acute care hospitals in the United States. The company offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services. It also provides outpatient services at urgent care centers, occupational medicine clinics, imaging centers, cancer centers, and ambulatory surgery centers. As of December 31, 2018, it owned or leased 113 hospitals, including 111 general acute care hospitals and 2 stand-alone rehabilitation or psychiatric hospitals with an aggregate of 18,227 licensed beds. Community Health Systems, Inc. was founded in 1985 and is headquartered in Franklin, Tennessee.

Market Stats

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-10-22 )

Largest Industry Peers for Medical Care

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HCA HCA Healthcare, Inc

+1.62 (+1.31%)

USD 42.16B 11.91 8.40
FMS Fresenius Medical Care AG & Co..

-2.03 (-5.93%)

USD 20.70B 9.26 17.14
UHS Universal Health Services, Inc

+1.06 (+0.73%)

USD 12.93B 16.71 10.01
DVA DaVita Inc

+0.55 (+0.94%)

USD 9.41B 72.19 9.00
CHE Chemed Corporation

-3.68 (-0.89%)

USD 6.65B 34.52 24.65
EHC Encompass Health Corporation

+0.86 (+1.29%)

USD 6.59B 21.47 10.97
AMN AMN Healthcare Services, Inc

+0.07 (+0.12%)

USD 2.75B 22.47 14.75
SEM Select Medical Holdings Corpor..

+0.30 (+1.75%)

USD 2.31B 16.18 11.72
THC Tenet Healthcare Corporation

N/A

USD 2.14B 22.20 7.38
MD MEDNAX, Inc

+0.10 (+0.43%)

USD 1.93B 10.00 7.60

ETFs Containing CYH

Symbol Name Weight Mer Price(Change) Market Cap
FNDA Schwab Fundamental U.S. S.. 0.00 % 0.25 %

+0.07 (+0.18%)

USD 3.31B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Care)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 58.16% 100% A+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.16% 100% A+ 95% A
Trailing 12 Months  
Capital Gain 51.19% 100% A+ 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.19% 100% A+ 96% A
Trailing 5 Years  
Capital Gain -91.92% 14% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -91.92% 14% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain -43.96% 6% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -43.96% 6% F N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.39% 38% F 26% F
Risk Adjusted Return -173.16% 6% F 1% F
Market Capitalization 0.49B 33% F 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Care)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio -14.09 100% A+ 100% A+
Price / Cash Flow Ratio 1.80 72% C- 80% B-
EV/EBITDA 11.29 39% F 43% F
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 7.23% 33% F 56% F
Return on Assets 3.11% 33% F 57% F
Debt to Equity Ratio -858.37% 82% B- 99% A+
Technical Ratios  
Short Ratio 6.87 28% F 16% F
Short Percent 30.77% 6% F 29% F
Beta 3.44 6% F 1% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Negative Book Value

The company has negative book value.